Rover Diagnostics was founded in 2018 by Samuel Sia and Mark Fasciano in collaboration with Columbia University. Based in New York City, Rover’s primary mission is to help meet the urgent global need for a cost-effective, highly sensitive, mass-produced point-of-care COVID-19 instrument and test kit system. Rover is a participant in the NIH RADx program to accelerate availability and capacity for COVID testing.